Loading
Life sciences · Journal article
Degrés · October 13, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
ABSTRACTThe human microbiome has emerged as a critical regulator of cancer initiation, progression,metastasis, and therapeutic response. Advances in metagenomics and molecular biology havedemonstrated that microbial communities residing in the gut and tumor microenvironmentinfluence carcinogenesis through inflammation, immune modulation, metabolic alteration,and genotoxicity. Dysbiosis, defined as an imbalance in microbial composition, has beenstrongly associated with colorectal, gastric, breast, pancreatic, lung, and liver cancers. Certainmicrobial species such as Helicobacter pylori, Fusobacterium nucleatum, and Bacteroidesfragilis contribute to tumour progression by activating oncogenic signalling pathways,suppressing host immunity, and producing carcinogenic metabolites. Furthermore, themicrobiome significantly affects responses to chemotherapy and immunotherapy, therebyinfluencing patient outcomes. Recent therapeutic strategies including probiotics, prebiotics,synbiotics, and faecal microbiota transplantation have shown promise in modulatingmicrobial composition to improve cancer treatment efficacy. This review summarizes currentknowledge regarding the role of the microbiome in cancer progression, underlying molecularmechanisms, interactions with anticancer therapies, and future therapeutic opportunities.